Ampicillin for DYT-1 Dystonia Motor Symptoms

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate if the antibiotic Ampicillin is safe and tolerated in patients that have generalized dystonia caused by the DYT-1 gene mutation, as compared to patients treated with a placebo. A placebo is a pill that looks and tastes the same as the real drug, but without the active ingredient. The second objective of this study is to determine if dystonia symptoms improve while on the study drug.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Collaborator: Tyler's Hope for a Dystonia Cure, Inc
• Treatments: Ampicillin

Criteria

Inclusion Criteria:

• DYT-1 dystonia, confirmed by genetic testing

• Between ages of 7 and 80 years

• BFM-DRS score greater than 6

Exclusion Criteria:

• Negative DYT-1 dystonia gene test

• Allergy to penicillins or cephalosporins

• Concurrent bacterial, viral or fungal infection at time of enrollment

• Pregnancy

• Inability to follow study protocol

• Lactose intolerance (placebo contains lactose powder)